||Isoquercitrin has anti-tumoral, antihypertensive, anti-osteoporosis, anti-allergy,
anti-inflammatory, and antiasthmatic activities, it also may be as a potential therapeutic agent against neurodegeneration in Parkinson's disease. Isoquercitrin is an inhibitor of Wnt/β-catenin that acts downstream of the β-catenin nuclear translocation; it is also a potential stimulator of bone mineralization used for prophylaxis of osteoporotic disorders. Isoquercitrin inhibited carbachol and leukotriene D4 -induced contraction in guinea-pig airways, and it induced hypotension in rats is an event dependent on the inhibition of angiotensin II generation by angiotensin converting enzyme (ACE). |
|Biochem Pharmacol. 2014 Jun 1;89(3):413-21. |
|Isoquercitrin and polyphosphate co-enhance mineralization of human osteoblast-like SaOS-2 cells via separate activation of two RUNX2 cofactors AFT6 and Ets1.[Pubmed: 24726443]|
|Isoquercitrin, a dietary phytoestrogen, is a potential stimulator of bone mineralization used for prophylaxis of osteoporotic disorders.
METHODS AND RESULTS:
Here we studied the combined effects of Isoquercitrin, a cell membrane permeable 3-O-glucoside of quercetin, and polyphosphate [polyP], a naturally occurring inorganic polymer inducing bone formation, on mineralization of human osteoblast-like SaOS-2 cells. Both compounds Isoquercitrin and polyP induce at non-toxic concentrations the mineralization process of SaOS-2 cells. Co-incubation experiments revealed that Isoquercitrin (at 0.1 and 0.3μM), if given simultaneously with polyP (as Ca(2+) salt; at 3, 10, 30 and 100μM) amplifies the mineralization-enhancing effect of the inorganic polymer. The biomineralization process induced by Isoquercitrin and polyP is based on two different modes of action. After incubation of the cells with Isoquercitrin or polyP the expression of the Runt-related transcription factor 2 [RUNX2] is significantly upregulated. In addition, Isoquercitrin causes a strong increase of the steady-state-levels of the two co-activators of RUNX2, the activating transcription factor 6 [ATF6] and the Ets oncogene homolog 1 [Ets1]. The activating effect of Isoquercitrin occurs via a signal transduction pathway involving ATF6, and by that, is independent from the induction cascade initiated by polyP.
This conclusion is supported by the finding that Isoquercitrin upregulates the expression of the gene encoding for osteocalcin, while polyP strongly increases the expression of the Ets1 gene and of the alkaline phosphatase. We show that the two compounds, polyP and Isoquercitrin, have a co-enhancing effect on bone mineral formation and in turn might be of potential therapeutic value for prevention/treatment of osteoporosis.
|Oncol Rep. 2015 Feb;33(2):840-8. |
|Isoquercitrin inhibits the progression of pancreatic cancer in vivo and in vitro by regulating opioid receptors and the mitogen-activated protein kinase signalling pathway.[Pubmed: 25434366]|
|Pancreatic cancer is a common malignant tumour that affects individuals worldwide. In recent years, the incidence and mortality rates of pancreatic cancer have continuously increased. Currently, the primary clinical treatment methods for pancreatic cancer include surgical resection, chemotherapy and radiotherapy. However, these treatment methods rarely produce satisfactory therapeutic outcomes. Extensive research has also proven that the effective components of several traditional Chinese medicines, particularly flavonoids extracted from plants, have significant antitumour effects. Isoquercitrin, which is one of the flavonoids found in Bidens pilosa extracts, has a significant antitumour effect.
However, the antitumour effect of Isoquercitrin and its mechanism of action remain unclear.
METHODS AND RESULTS:
The objective of the present study was to investigate the effect of Isoquercitrin on the progression of pancreatic cancer and to further understand the biological characteristics of the participation of Isoquercitrin in the progression of pancreatic cancer. In vitro, we found that a therapeutic dose of Isoquercitrin significantly inhibited proliferation, promoted apoptosis and induced cell cycle arrest within the G1 phase in pancreatic cancer cells. Isoquercitrin activated caspase-3, -8 and -9 and reduced the mitochondrial membrane potential. In addition, Isoquercitrin inhibited the expression level of the δ opioid receptor; however, Isoquercitrin had no effect on the κ and μ opioid receptors. Furthermore, Isoquercitrin inhibited extracellular signal-regulated kinase (ERK) phosphorylation and promoted c-Jun N-terminal kinase (JNK) phosphorylation. In vivo, we found that a therapeutic dose of Isoquercitrin significantly inhibited xenograft growth in nude mice.
In summary, the present study demonstrated that Isoquercitrin inhibits human pancreatic cancer progression in vivo and in vitro and that its molecular mechanism may be closely related to opioid receptors and to the activation of the mitogen-activated protein kinase (MAPK) signalling pathway.
|Eur J Pharmacol. 2005 Oct 17;522(1-3):108-15. |
|Isoquercitrin from Argemone platyceras inhibits carbachol and leukotriene D4-induced contraction in guinea-pig airways.[Pubmed: 16202993]|
|Argemone platyceras is used in Mexico as a remedy for cough, bronchitis and pneumonia. The present study was performed to investigate the pharmacological anti-asthmatic properties of Argemone platyceras on airways and to identify its active principles.
METHODS AND RESULTS:
Methanol extracts of leaves and flowers, subsequent organic and aqueous extraction phases, and silica gel chromatography fractions were assayed on the carbachol-induced response, and/or on ovalbumin antigenic challenge, and on leukotriene D(4)-induced response of tracheae from sensitized and non-sensitized guinea-pigs. Methanol extracts, ethyl-acetate phase, and its fractions 6 and 7 inhibited the carbachol-induced contractile response. Isoquercitrin and rutin were the main compounds found in fractions 6 and 7 respectively. Isoquercitrin (fraction 6) abolished the response to ovalbumin, and decreased the contractile response to leukotriene D(4).
Because of its effect on carbachol-induced contractile response, on the late-phase response to ovalbumin, and on leukotriene D(4)-induced contractile response, Isoquercitrin might be highly useful in treatment of asthma.